Articles from NodThera

Data published in the Journal of the American College of Cardiology Represents first peer-reviewed publication of clinical data demonstrating reductions in cardiometabolic risk markers with NLRP3 inhibitor 

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, today announced that data from the cardiometabolic Phase 1b clinical trial of its lead candidate, ruvonoflast, previously known as NT-0796, has been accepted for a late-breaking oral presentation at the 94th European Atherosclerosis Society (EAS) Congress being held May 24-27, 2026 in Athens, Greece.

BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, today announced participation in the following investor conferences:

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, today announced that Geoff McDonough, M.D., Chief Executive Officer of NodThera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held February 25-26, 2026, in a virtual format.

Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced that Chris Guiffre, J.D., M.B.A., Chief Financial Officer of NodThera, will present at the 44th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2026, in San Francisco, CA.

Seasoned physician-executive with global biopharma leadership experience joins Board at a pivotal stage of clinical and corporate development